FDA issued a warning letter to Genzyme’s Ireland manufacturing site, raising quality and data-integrity concerns linked to manufacturing controls. The letter, tied to the site now owned by Sanofi, highlighted issues related to data integrity and other quality-related deficiencies, according to the report. The action reflects ongoing regulatory emphasis on traceability and reliability of data across biologics manufacturing operations. Even when sites operate under existing product portfolios, warning letters can affect manufacturing readiness, batch release timelines, and downstream clinical and commercial supply. For biotech manufacturing and quality leaders, the Genzyme Ireland warning reiterates that data governance is treated as a core part of compliance—not a peripheral issue—and can drive operational remediation plans. The situation also signals the likelihood of increased regulator scrutiny for manufacturing records, change control, and inspection readiness at contract and internal biologics facilities.